drugset
drugset / Trial / NCT06597799

First-in-human Study of MRT-6160 in Healthy Subjects

NCT06597799 ↗

Phase 1 Completed 108 enrolled Monte Rosa Therapeutics, Inc
RandomizedSequentialQuadruple-blindTreatment

Summary

The principal aim of this study is to obtain safety and tolerability data when MRT-6160 is administered orally as single and multiple doses to healthy subjects. This information, together with the pharmacokinetic (PK) data, will help establish the doses and dosing regimen suitable for future studies in patients. The study drug, MRT-6160, is experimental. This is the first study in which MRT-6160 will be given to humans. Part 1: Subjects will receive a single oral dose of MRT-6160 or placebo on Day 1 Part 2: Subjects will receive multiple oral doses of MRT-6160 or placebo for 7 consecutive days

Timeline

Start
2024-08-07
Primary completion
2025-04-10
Completion
2025-04-10

Drugs

EvaluationDrugModalityDoseRoute
Subject MRT-6160 Unknown — Oral

Indications

No indication recorded.